Ferhat GÖKAY, DİLEK BERKER, Ayşe ARDUÇ, Ufuk ÖZUĞUZ, Serhat IŞIK, Iffet DAGDELEN, Mazhar Müslüm TUNA, Serdar GÜLER

Predictive Factors of Malignancy in Residual Thyroid Tissue after Partial Thyroidectomy in Patients with Differentiated Thyroid Cancer

Although partial thyroidectomy has lower operative risk, it potentially caries the risk of leaving residual malignancy. The aim of this study was to establish malignancy rate in residual thyroid tissue in patients with differentiated thyroid cancer (DTC) who underwent partial thyroid surgery and subsequently had completion thyroidectomy. We also investigated a number of clinical and biochemical factors that may anticipate the presence of malignancy in the thyroid remnant. Data of 58 patients with DTC who underwent completion thyroidectomy were retrospectively analyzed. Patients were divided into 2 groups based on the residual tissue pathology after completion thyroidectomy; the first group consisted of patients with malignant residual tissue, and the second group consisted of patients with benign residual tissue. Tumor histopathology type and serum thyroglobulin levels before completion thyroidectomy were compared between the two groups. Among 58 patients, 13 (22.4%) patients were found to have malignant residual tissue after completion thyroidectomy. No significant differences were found between the groups with respect to age, serum thyroglobulin level before completion thyroidectomy, primary tumor type, tumor size, bilateralism, multifocality, arterial invasion, thyroid capsular invasion, and extrathyroidal invasion. Residual thyroid volume was higher in patients with malignant residual tissue. In binary logistic regression analysis, residual thyroid volume was the only predictor factor for the presence of malignancy in the thyroid remnant. Malignancy in residual thyroid tissue is not uncommon. Thyroid remnant volume may be predictive of malignancy in residual thyroid tissue

PDF

___

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. In: Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Pres, 2004;50-66.

2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

3. Wang TS, Roman SA, Sosa JA. Differentiated thyroid cancer: an update. Curr Opin Oncol. 2011;23(1):7-12.

4. Barzon L, Boscaro M, Pacenti M, Taccaliti A, Palù G. Evaluation of circulating thyroidspecific transcripts as markers of thyroid cancer relapse. Int J Cancer. 2004;110(6):914- 20.

5. Brown MC, Spencer R: Thyroid gland volume estimated by use of ultrasound in addition to scintigraphy. Acta Radiol Oncol Radiat Phys Biol 1978;17(4):337-41.

6. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-24.

7. Wax MK, Briant TD. Completion thyroidectomy in the management of welldifferentiated thyroid carcinoma. Otolaryngol Head Neck Surg. 1992;107(1):63-8.

8. Mishra A, Mishra SK. Total thyroidectomy for differentiated thyroid cancer: primary compared with completion thyroidectomy. Eur J Surg 2002;168(5):283-7.

9. Turanli S, Aslan S, Cetin A. Clinical significance of residual occult malignancy in thyroid carcinoma. Am J Otolaryngol. 2011;32(5):398-401.

10. Kupferman ME, Mandel SC, DiDonato L, Weber RS. Safety of completion thyroidectomy following unilateral lobectomy for well-differentiated thyroid cancer. Laryngoscope. 2002;112(7 Pt 1):1209-12.

11. Alzahrani AS, Al Mandil M, Chaudhary MA, Ahmed M, Mohammed GE. Frequency and predictive factors of malignancy in residual thyroid tissue and cervical lymph nodes after partial thyroidectomy for differentiated thyroid cancer. Surgery. 2002;131(4):443-9.

12. Eroğlu A, Unal M, Kocaoğlu H. Total thyroidectomy for differentiated thyroid carcinoma: primary and secondary operations. Eur J Surg Oncol. 1998;24(4):283-7.

13. Chao TC, Jeng LB, Lin JD, Chen MF. Completion thyroidectomy for differentiated thyroid carcinoma. Otolaryngol Head Neck Surg. 1998;118(6):896-9.

14. Eroglu A, Berberoglu U, Buruk F, Yıldırım E. Completion thyroidectomy for differentiated thyroid carcinoma. J Surg Oncol. 1995;59(4):261-7.

15. Auguste LJ, Attie NJ. Completion thyroidectomy for initially misdiagnosed thyroid cancer. Otolaryngol Clin North Am. 1990;23(3):429-39.

16. Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, Shong YK. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf). 2004;61(1):145-8.

17. Turanli S, Aslan S, Cetin A. Clinical significance of residual occult malignancy in thyroid carcinoma. Am J Otolaryngol. 2011;32(5):398-401.